DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: DETROL LA

Summary for Tradename: DETROL LA

Patents:3
Applicants:1
NDAs:1
Suppliers: see list6
drug
patent expirations by year for
 DETROL LA

Pharmacology for Tradename: DETROL LA

Clinical Trials for: DETROL LA

A Study to Evaluate Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)
Status: Recruiting Condition: Overactive Bladder (OAB)

Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
Status: Completed Condition: Overactive Bladder

Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder
Status: Completed Condition: Overactive Bladder

Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients
Status: Completed Condition: Overactive Bladder

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
Status: Completed Condition: Healthy

Pharmacokinetics and Relative Bioavailability Study
Status: Completed Condition: Urinary Bladder, Overactive

Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine
Status: Completed Condition: Pharmacokinetics of Mirabegron and Tolterodine; Healthy

Efficacy and Safety Study of Dutasteride Combined With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)
Status: Active, not recruiting Condition: BPH

A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
Status: Completed Condition: Overactive Bladder

A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.
Status: Terminated Condition: Urinary Incontinence

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn
DETROL LA
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228Dec 22, 2000RXNo6,630,162*PED<disabled>Y<disabled>
Pharmacia And Upjohn
DETROL LA
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228Dec 22, 2000RXNo6,770,295*PED<disabled>Y<disabled>
Pharmacia And Upjohn
DETROL LA
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228Dec 22, 2000RXNo6,911,217*PED<disabled>Y<disabled>
Pharmacia And Upjohn
DETROL LA
tolterodine tartrate
CAPSULE, EXTENDED RELEASE;ORAL021228Dec 22, 2000RXYes6,630,162*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: DETROL LA

Drugname Dosage Strength RLD Submissiondate
tolterodine tartrateExtended-release Capsules2 mg and 4 mgDetrol LA7/30/2007

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc